{
  "paper_metadata": {
    "pmid": "32486089",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for BRCA2, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.5224C>T",
      "protein_notation": "p.Arg174Cys",
      "genomic_position": "rs41293469",
      "clinical_significance": "VUS",
      "patients": {
        "count": 346,
        "demographics": "334 with breast and/or ovarian cancer, 12 with prostate cancer",
        "phenotype": "hereditary breast and/or ovarian cancer syndrome"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 0,
        "unaffected_count": 1,
        "uncertain_count": 0,
        "penetrance_percentage": 0.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "unknown",
          "affected_status": "unaffected",
          "phenotype_details": "no additional pathogenic event in the germline samples",
          "evidence_sentence": "Case analysis of the likely pathogenic reclassified VUS variant BRCA1 p.V1653L (rs80357261) by MH BRCA revealed in our cohort three breast and/or ovarian cancer patients with otherwise no additional pathogenic event in the germline samples."
        }
      ],
      "functional_data": {
        "summary": "Functional assays indicated no damaging effect.",
        "assays": [
          "complementation assay",
          "HR capacity",
          "cisplatin sensitivity"
        ]
      },
      "segregation_data": "Not specified",
      "population_frequency": "Not specified",
      "evidence_level": "Moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "Variant reclassified from pathogenic to VUS.",
      "key_quotes": [
        "the missense variants BRCA2 p.R174C (rs41293469) ... were reclassified in MH BRCA from pathogenic to VUS"
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.3065_3066del",
      "protein_notation": "p.N1023_I1024del",
      "genomic_position": "rs730881605",
      "clinical_significance": "VUS",
      "patients": {
        "count": 346,
        "demographics": "334 with breast and/or ovarian cancer, 12 with prostate cancer",
        "phenotype": "hereditary breast and/or ovarian cancer syndrome"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 0,
        "unaffected_count": 1,
        "uncertain_count": 0,
        "penetrance_percentage": 0.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "unknown",
          "affected_status": "unaffected",
          "phenotype_details": "no additional pathogenic event in the germline samples",
          "evidence_sentence": "the small deletion BRCA2 p.N1023_I1024del (rs730881605) ... were reclassified in MH BRCA from pathogenic to VUS"
        }
      ],
      "functional_data": {
        "summary": "Functional assays indicated no damaging effect.",
        "assays": [
          "complementation assay",
          "HR capacity",
          "cisplatin sensitivity"
        ]
      },
      "segregation_data": "Not specified",
      "population_frequency": "Not specified",
      "evidence_level": "Moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "Variant reclassified from pathogenic to VUS.",
      "key_quotes": [
        "the small deletion BRCA2 p.N1023_I1024del (rs730881605) ... were reclassified in MH BRCA from pathogenic to VUS"
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.10255C>T",
      "protein_notation": "p.R3052Q",
      "genomic_position": "rs80359171",
      "clinical_significance": "likely benign",
      "patients": {
        "count": 346,
        "demographics": "334 with breast and/or ovarian cancer, 12 with prostate cancer",
        "phenotype": "hereditary breast and/or ovarian cancer syndrome"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 0,
        "unaffected_count": 1,
        "uncertain_count": 0,
        "penetrance_percentage": 0.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "unknown",
          "affected_status": "unaffected",
          "phenotype_details": "no damaging effect in the complementation assay",
          "evidence_sentence": "the variant BRCA2 p.R3052Q (rs80359171) to likely benign"
        }
      ],
      "functional_data": {
        "summary": "Functional assays indicated no damaging effect.",
        "assays": [
          "complementation assay",
          "HR capacity",
          "cisplatin sensitivity"
        ]
      },
      "segregation_data": "Not specified",
      "population_frequency": "Not specified",
      "evidence_level": "Moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "Variant classified as likely benign.",
      "key_quotes": [
        "the variant BRCA2 p.R3052Q (rs80359171) to likely benign"
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.10230_10231del",
      "protein_notation": "p.N3407fs",
      "genomic_position": null,
      "clinical_significance": "VUS",
      "patients": {
        "count": 346,
        "demographics": "334 with breast and/or ovarian cancer, 12 with prostate cancer",
        "phenotype": "hereditary breast and/or ovarian cancer syndrome"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 0,
        "unaffected_count": 1,
        "uncertain_count": 0,
        "penetrance_percentage": 0.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_4",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "unknown",
          "affected_status": "unaffected",
          "phenotype_details": "no additional pathogenic event in the germline samples",
          "evidence_sentence": "the last exon frameshift BRCA2 p.N3407fs were reclassified in MH BRCA from pathogenic to VUS"
        }
      ],
      "functional_data": {
        "summary": "Functional assays indicated no damaging effect.",
        "assays": [
          "complementation assay",
          "HR capacity",
          "cisplatin sensitivity"
        ]
      },
      "segregation_data": "Not specified",
      "population_frequency": "Not specified",
      "evidence_level": "Moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "Variant reclassified from pathogenic to VUS.",
      "key_quotes": [
        "the last exon frameshift BRCA2 p.N3407fs were reclassified in MH BRCA from pathogenic to VUS"
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 4,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant BRCA2 variants were extracted with detailed penetrance data."
  }
}